David Southwell
Direttore/Membro del Consiglio presso ROCKET PHARMACEUTICALS, INC.
Patrimonio netto: 4 M $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Stephanie Sullivan | F | 51 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | - |
James Hunt | M | 72 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 7 anni |
Gaurav D. Shah | M | 49 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 9 anni |
Gavin MacBeath | M | 54 | 6 anni | |
Matthew Klein | M | 52 | 5 anni | |
Timothy Barberich | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 7 anni |
Nancy Hawthorne | F | 72 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 15 anni |
Chris Flynn | M | 50 | 17 anni | |
John Anthony Sommers | M | 85 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 7 anni |
Kinnari Patel | M | 46 |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | 8 anni |
Keith Hughes | M | 77 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 8 anni |
David Keith Downes | M | 84 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | 10 anni |
Carsten Boess | M | 57 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 8 anni |
John Militello | M | 50 | 6 anni | |
Richard Simon | M | - |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | - |
Allan Jacobson | M | 78 | 26 anni | |
Sabrina Rusnak-Carlson | F | 45 | 9 anni | |
Michael Schmertzler | M | 72 | 23 anni | |
Christine Utter | F | 46 | 14 anni | |
Neil Almstead | M | 57 | 24 anni | |
Glenn Steele | M | 79 | 9 anni | |
Katina Dorton | F | 66 | 3 anni | |
Mary Smith | F | 61 | 3 anni | |
Martin Wilson | M | 47 | 3 anni | |
Melodie R. Domurad | M | 66 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 16 anni |
Jonathan Schwartz | M | 60 | 8 anni | |
Zoran Zdraveski | M | 54 | 3 anni | |
Stephanie Okey | F | 64 | 6 anni | |
Gayatri R. Rao | M | - | 6 anni | |
Ellen Welch | M | - | - | |
Gabriela Gruia | M | 67 | 3 anni | |
Leiden Dworak | M | - | 2 anni | |
Alex Simon | M | - |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | - |
Mark White | M | 57 | 1 anni | |
R. Woods | M | 57 | 1 anni | |
Margareta Elisabeth Björk | M | 63 | 4 anni | |
Chester Koczynski | M | - |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 anni |
Cynthia Smith | F | 55 | 5 anni | |
Deborah McAneny | F | 65 | 9 anni | |
John Pottage | M | 71 | 6 anni | |
Stephen Biggar | M | 53 | 3 anni | |
Mark Boulding | M | 63 | 22 anni | |
Emma Reeve | F | 63 | 6 anni | |
Naveen Yalamanchi | M | 47 | 6 anni | |
Gotham Makker | M | 50 | 6 anni | |
Jerome Zeldis | M | 74 | 12 anni | |
Martin Rexroad | M | - | 11 anni | |
Dan Troy | M | 64 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 12 anni |
Frank Thomas | M | 54 | 7 anni | |
Alethia Young | F | 45 | 2 anni | |
Pedro Granadillo | M | 77 | 6 anni | |
James D. Kern | M | 57 | 10 anni | |
Alexandra Glucksmann | M | 65 |
Sensorium Therapeutics, Inc.
Sensorium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sensorium Therapeutics, Inc. is a biotechnology company based in Massachusetts. Sensorium Therapeutics leverages cutting-edge chemistry, neuroscience, and machine learning to develop nature-inspired psychoactive medicines for mental health. The American company's groundbreaking biodynamic discovery platform™ rapidly identifies, reproduces, adapts, and enhances targeted molecules to deliver transformational benefits to patients around the world. The company completed a $30m series A financing in late 2023 led by Santé Ventures, with participation from Route 66 Ventures, CU Healthcare Innovation Fund, and others. The company was founded by Jerrold F. Rosenbaum, Jacob Hooker, Richard Simon, Alex Simon, and Stephen Haggarty. Richard Simon has been the CEO since incorporation. | 1 anni |
Fady Malik | M | 59 | 2 anni | |
James Ray Fellows | M | 59 |
THL Credit Secured Floating Rate Debt Ltd.
THL Credit Secured Floating Rate Debt Ltd. Financial ConglomeratesFinance THL Credit Secured Floating Rate Debt, Ltd. operates as a closed-end management investment company. It is managed by THL Credit Advisors LLC, which provides the administrative services. The company intends to elect to be treated as a business development company. THL Credit Secured Floating Rate Debt was founded on June 26, 2013 and is headquartered in Boston, MA. | - |
Richard J. Faleschini | M | 77 |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | 20 anni |
Will Febbo | M | 55 |
Panel Intelligence LLC
Panel Intelligence LLC Internet Software/ServicesTechnology Services Panel Intelligence LLC offers a powerful online health care and medical research platform providing clients greater strategic direction for investment decisions, product development, and marketing. The private company is based in Cambridge, MA. William J. Febbo has been the CEO of the company since 2009. Panel Intelligence was acquired by Panel Intelligence /Private Group/ from Merriman Holdings, Inc. on January 30, 2009 for $1.10 million. | 15 anni |
Raj Prabhakar | M | 50 | 7 anni | |
Kevin Giordano | M | - | 3 anni | |
Isabel Carmona | F | - | 3 anni | |
Jeanine Clemente | F | - | 5 anni | |
Murad Husain | M | - | 10 anni | |
Pierre Gravier | M | 39 | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Terrence Olson | M | 56 | 12 anni | |
Christoph H. Westphal | M | 56 | 3 anni | |
Dale Ritter | M | 73 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
Brian Silver | M | 55 | 2 anni | |
Lea Hachigian | M | - | 3 anni | |
Antony Loebel | M | 64 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | - |
Brian Batchelder | M | - | - | |
Adrian Adams | M | 73 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 4 anni |
Sam Tillinghast | M | 61 | - | |
Michael Loberg | M | 76 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 8 anni |
Ittai Harel | M | 56 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 11 anni |
Deirdre Connelly | F | 63 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 3 anni |
Marcio Souza | M | 45 | 6 anni | |
Lisa McGrath | F | - |
BioSphere Medical, Inc.
BioSphere Medical, Inc. Medical SpecialtiesHealth Technology BioSphere Medical, Inc. develops, manufactures and markets microsphere technology to medical applications. The company uses microsphere technology to develop its products for medical applications using embolotherapy techniques. It offers Embosphere Microspheres for uterine fibroids, hypervascularized tumors and other arteriovenous malformations, EmboGold Microspheres for Hypervascularized tumors and arteriovenous malformations, EmboCath Infusion Catheter and Segway Guidewire for peripheral embolization procedures and HepaSphere Microspheres for liver cancer. The company was founded in 1993 and is headquartered in Rockland, MA. | - |
Mark Iwicki | M | 57 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 5 anni |
William McVicar | M | 66 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 18 anni |
Claudine Prowse | M | - |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 3 anni |
Mayur Kasetty | M | - | 4 anni | |
Joel D. Sendek | M | 57 | 2 anni | |
H. Watkins | M | 71 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD. | 8 anni |
Jim O'Shea | M | 74 |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | 8 anni |
Stuart Peltz | M | 64 | 25 anni | |
Argeris Karabelas | M | 71 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 anni |
Michael Bell | M | 68 |
inVentiv Health, Inc.
inVentiv Health, Inc. Miscellaneous Commercial ServicesCommercial Services inVentiv Health, Inc. provides outsourced product development and commercialization services. It operates its business through the following segments: Clinical and Commercial. The Clinical segment clinical offers a continuum of services spanning phases I-IV of clinical development to the changing needs of pharmaceutical, biotechnology, diagnostic and medical device clients. The Commercial segment consists of selling solution services, communications, patient outcomes and consulting service offerings. The company was founded in 1999 and is headquartered in Burlington, MA. | 2 anni |
Cláudia Hirawat | F | 53 | 15 anni | |
Cameron McDonough | M | 53 | 5 anni | |
Emily Hill | F | 44 | - | |
Devang Vallabhdas Kantesaria | M | 51 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 anni |
Martin Vogelbaum | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 6 anni |
Michael L. Kranda | M | 69 | 12 anni | |
Dawn Svoronos | F | 70 | 6 anni | |
Richard H. Aldrich | M | 69 | 2 anni | |
Megan Sniecinski | F | 43 | 5 anni | |
Anu Bhattacharyya | F | - | - | |
Clarence Machado | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 2 anni |
Richard Spivey | M | 74 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
Adam Koppel | M | 54 | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David Southwell
- Contatti personali